BTIG analyst Jeet Mukherjee initiated coverage of Perspective Therapeutics (CATX) with a Buy rating and $14 price target The firm, which views Perspective as “a leader in the next-gen radiopharmaceutical space,” sees room for shares to appreciate headed into key catalysts at ESMO and into 2026 across key programs. Perspective’s investment in a U.S. regional manufacturing network, coupled with deep technical expertise in lead based radiopharmaceuticals, gives it high barriers to entry and scarcity value despite the radiopharmaceutical space becoming increasingly competitive, the analyst tells investors.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CATX:
- Positive Buy Rating for Perspective Therapeutics Driven by Promising Clinical Progress and Market Potential of FAP-Targeted Therapy
- Perspective Therapeutics announces first patient treated with PSV359
- Perspective Therapeutics Updates Radiopharmaceutical Advancements
- Optimistic Buy Rating for Perspective Therapeutics Driven by Promising Trial Results and Upcoming Catalysts
- Perspective Therapeutics: Promising Developments and Strong Buy Rating Amidst Encouraging Clinical Trial Results